Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCS2103
- Development stage
- Preclinical
- Lead developer
- PharmaCept
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
MCS2103 is a hydrogel-based product in the design verification stage, developed by Magle Pharmacept for advanced wound care. It is formulated as an easy-to-use and effective hydrogel, designed to promote wound healing. The product utilizes GelSpheres technology and is intended for use in the management of wounds, likely by providing a moist environment conducive to healing and potentially delivering active agents locally.
Beyond the preview
Go deeper on MCS2103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCS2103.